Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer

Rhea-AI Summary

Cardiff Oncology (Nasdaq: CRDF) will host a key opinion leader webinar on March 25, 2026 at 4:30 p.m. ET focused on first-line RAS-mutated metastatic colorectal cancer (mCRC).

The session features KOLs Scott Kopetz, M.D., Ph.D., Heinz-Josef Lenz, M.D., and interim CEO Mani Mohindru, PhD, discussing onvansertib clinical data and its potential role in mCRC management.

Key Figures

Webinar date: March 25, 2026 Webinar time: 4:30 p.m. ET

2 metrics

Webinar date March 25, 2026 KOL webinar on first-line RAS-mutated mCRC

Webinar time 4:30 p.m. ET Start time for KOL webinar

Market Reality Check

Price: $1.82 Vol: Volume 713,308 is at 0.92...

normal vol

$1.82 Last Close

Volume Volume 713,308 is at 0.92x the 20-day average of 778,565 shares. normal

Technical Shares at $1.82 are trading below the 200-day MA of $2.52 and sit 60.04% below the 52-week high, but 22.97% above the 52-week low.

Peers on Argus

Momentum scanner shows only AVTX in motion, down 1.55% with no related news. No ...

1 Down

Momentum scanner shows only AVTX in motion, down 1.55% with no related news. No evidence that this KOL webinar headline is part of a broader sector move.

Historical Context

5 past events · Latest: Feb 26 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 26	Investor conferences	Neutral	-1.0%	Participation in three March 2026 investor conferences highlighted to the market.
Feb 24	Earnings & trial data	Positive	+12.3%	Full-year 2025 results and strong Phase 2 onvansertib efficacy in first-line mCRC.
Feb 19	Conference presentation	Neutral	+4.5%	Announcement of presentation at Oppenheimer healthcare conference and investor meetings.
Jan 27	Phase 2 update	Positive	-32.0%	Positive randomized Phase 2 CRDF-004 data for onvansertib in RAS-mutated mCRC.
Jan 27	Leadership changes	Negative	-32.0%	CEO and CFO departures with interim CEO appointment amid transition to late-stage development.

Pattern Detected

Positive clinical and earnings updates have sometimes led to strong moves, but at least one major positive trial readout saw a sharp divergence between news tone and price reaction.

Recent Company History

Over recent months, Cardiff Oncology has highlighted advancing Phase 2 data for onvansertib in first-line RAS‑mutated mCRC and prepared for a registrational path. A Jan 27, 2026 Phase 2 update and concurrent leadership changes triggered a large selloff despite positive trial data. Later, full-year 2025 results with favorable efficacy metrics on Feb 24, 2026 saw a 12.35% gain. The current KOL webinar fits an ongoing effort to showcase onvansertib’s data to clinicians and investors.

Market Pulse Summary

This announcement details a KOL webinar on March 25, 2026 at 4:30 p.m. ET, focused on the evolving f...

Analysis

This announcement details a KOL webinar on March 25, 2026 at 4:30 p.m. ET, focused on the evolving first-line RAS-mutated metastatic colorectal cancer landscape and existing onvansertib data. It follows recent Phase 2 updates, leadership changes, and earnings disclosures that outlined both efficacy results and the development path. Investors may watch for how experts contextualize onvansertib versus standard-of-care regimens and how this scientific discussion supports future regulatory and registrational plans.

Key Terms

plk1 inhibition, key opinion leader

2 terms

plk1 inhibition medical

"a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies"

PLK1 inhibition means blocking the activity of the enzyme Polo‑like kinase 1, a protein that helps cells divide. For investors, it signals a drug approach aimed at slowing or stopping fast‑growing tumors by disrupting the cell’s “division machinery,” but it also raises safety and trial‑success questions because the same process is important in healthy tissues; clinical results and side‑effect profiles drive the investment impact.

key opinion leader technical

"announced that the Company will host a key opinion leader (KOL) webinar"

A key opinion leader is an individual whose insights, expertise, or influence significantly shape the opinions and decisions of others within a particular field or community. For investors, they are like trusted guides whose views can impact market trends or perceptions, making their perspectives important to watch. Their influence often stems from experience, reputation, or widespread respect among peers.

AI-generated analysis. Not financial advice.

SAN DIEGO, March 20, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that the Company will host a key opinion leader (KOL) webinar to discuss the emergent treatment landscape in first-line RAS-mutated metastatic colorectal cancer (mCRC). The webinar will take place on Wednesday, March 25th, 2026, at 4:30 p.m. ET.

The webinar will feature KOLs Scott Kopetz, M.D., Ph.D., FACP and Heinz-Josef Lenz, M.D., who will join Mani Mohindru, PhD, interim Chief Executive Officer, to discuss onvansertib's existing clinical data and its potential as a novel therapeutic approach in the management of mCRC.

About the KOLs

Scott Kopetz, M.D., Ph.D., FACP, is a Professor in the Department of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center and an internationally recognized leader in colorectal cancer research and translational oncology. Dr. Kopetz’s work has helped establish new treatment approaches for molecularly defined colorectal cancers, including therapies targeting BRAF-mutated metastatic disease. He serves in multiple national leadership roles supporting gastrointestinal cancer research and clinical trial development and has led numerous Phase I–III clinical studies focused on improving outcomes for patients with GI malignancies. His research integrates molecular profiling and translational science to advance precision medicine strategies and overcome treatment resistance in colorectal cancer.

Heinz Josef-Lenz, M.D., is a University Professor of Medicine, Population and Public Health Sciences and Cancer Biology; Professor of Medicine and Preventive Medicine of USC. He serves as Co-Leader of the Gastrointestinal Cancers Program and Co-Director of the USC Center for Cancer Drug Development. Dr. Lenz’s research focuses on molecular mechanisms of cancer development, drug resistance, and biomarker-driven treatment approaches in gastrointestinal cancers, including colorectal cancer. He has authored numerous peer-reviewed publications and holds leadership roles across national oncology research initiatives, including service on National Cancer Institute committees and cooperative clinical trial groups guiding translational and clinical research in GI oncology.

KOL Webinar Information

Interested parties can register for and access the live webcast by visiting the “Events” section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the discussion.

About Cardiff Oncology, Inc.  
Cardiff Oncology is a clinical-stage biotechnology company advancing innovative cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Our lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (“mCRC”), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, we aim to overcome treatment resistance and deliver improved clinical outcomes for patients.

For more information, please visit https://www.cardiffoncology.com.

Investor Contact: 
Candice Masse 
Astr Partners 
candice.masse@astrpartners.com   

Media Contact:  
Amy Bonanno  
Lyra Strategic Advisory  
abonanno@lyraadvisory.com 

FAQ

When is Cardiff Oncology's (CRDF) KOL webinar on first-line RAS-mutated mCRC scheduled?

The webinar is scheduled for Wednesday, March 25, 2026 at 4:30 p.m. ET. According to the company, the live session will present expert discussion of onvansertib clinical data and treatment context for first-line RAS-mutated metastatic colorectal cancer.

Who will speak at Cardiff Oncology's (CRDF) March 25, 2026 webinar on onvansertib?

Speakers include KOLs Scott Kopetz, M.D., Ph.D., and Heinz-Josef Lenz, M.D., plus interim CEO Mani Mohindru, PhD. According to the company, they will discuss existing clinical data and potential therapeutic roles for onvansertib in mCRC.

What topics will Cardiff Oncology (CRDF) cover in the KOL discussion on onvansertib?

The webinar will cover the emergent treatment landscape and onvansertib's existing clinical data in first-line RAS-mutated mCRC. According to the company, experts will discuss clinical interpretation and potential implications for patient management and research directions.

How can investors or clinicians attend Cardiff Oncology's (CRDF) March 25 webinar?

Interested parties can join the live KOL webinar on the scheduled date and time; registration details are provided by the company. According to the company, the session is aimed at clinicians and stakeholders interested in onvansertib and mCRC treatment updates.

Will Cardiff Oncology (CRDF) present new onvansertib trial results during the March 25, 2026 webinar?

The webinar will discuss onvansertib's existing clinical data rather than announce new trial results. According to the company, the focus is expert interpretation of current data and the evolving first-line RAS-mutated mCRC landscape.

Why is Cardiff Oncology's (CRDF) KOL webinar relevant to mCRC stakeholders and investors?

The webinar offers expert context on onvansertib within first-line RAS-mutated mCRC, informing clinical and investment perspectives. According to the company, KOL insights may clarify clinical positioning and next-step considerations for the therapy's development.